Continued to lead the Crohn's Disease and EoE programs for etrasimod and integrated those Arena teams into the Pfizer system following the Arena/Pfizer merger.

Led etrasimod Crohn's Disease Phase 2/3 "program in a protocol" seamless design study. Also led the etrasimod eosinophilic esophagitis (EoE) program though the end of Phase 2b. Filed for and received FDA Orphan Designation for the EoE indication.Arena was acquired by Pfizer in March 2022.

Global regulatory strategy and submissions (CTAs, INDs, and NDAs) for small molecule, peptide, gene therapy, and monoclonal antibody studies in rheumatoid arthritis, asthma, COPD, acute heart failure, chronic heart failure, diabetic nephropathy, diabetes, inherited retinal disease, rare and orphan disease, and obesity. * Member of the canagliflozin regulatory team that gained FDA approval of Invokana (first-in-class SGLT2 inhibitor in the US). * Led the filing and gained FDA approval of the twice-daily Invokamet NDA (first-in-class SGLT2 inhibitor + metformin immediate release fixed dose combination in the US).* Led the filing and gained FDA approval of the once-daily Invokamet XR NDA (first-in-class SGLT2 inhibitor + metformin extended release fixed dose combination in the US).

Global regulatory strategy and submissions for early drug development through proof of concept Phase 2a clinical studies in multiple indications.

Managed global ethics and regulatory strategy and submissions and device quality issues for global drug-device combination oncology program.

Managed vendors, contracts, ethics submisions, and regulatory submissions for global drug-device combination oncology program.

Negotiated and executed hundreds of site contracts and budgets for various Pharma companies and indications.